Angion Biomedica Is ‘Better Positioned’ Than Peers Despite Trial Failure, HC Wainwright Thinks So
HC Wainwright has removed Angion Biomedica Corp’s (NASDAQ:ANGN) former lead candidate, ANG-3777, in acute kidney injury (AKI), from its valuation…